About Immix Biopharma Inc
- Industry: Biotechnology
- Exchange: NASDAQ NMS - GLOBAL MARKET
- Country: US
- Website: https://immixbio.com/
Frequently Asked Questions
What is the 52-week range for IMMX?
The 52-week high is $15.1 and the 52-week low is $1.995.
What is the P/E ratio for IMMX?
The P/E ratio data is currently unavailable.
What is the dividend yield for IMMX?
This company does not currently pay a dividend or the data is unavailable.
What is the Return on Equity (ROE)?
The trailing twelve months (TTM) Return on Equity is -38.44%.
What is the Net Profit Margin?
Net Margin data is currently unavailable.
What is the Price to Book (P/B) Ratio?
The annual Price to Book ratio stands at 2.94.
Analyst Recommendation Trends
Wall Street analyst consensus for IMMX over the last few months:
Latest IMMX News
Immix Biopharma Announces Closing of $125 Million Underwritten Offering of Common Stock
– Financing includes leading U.S. biotechnology institutional investors and mutual funds –LOS ANGELES, CA, Sept. 30, 2026 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “we” or “us” or “IMMX”), a global leader in relapsed/refractory AL Amyloidosis, today announced the closing of its previously announced underwritten registered offering of 11,363,637 shares of its common stock at a public offering price of $11.00 per share. The net proceeds to Immix from the offering, after ded
BofA Raises Odds Of Success For Immix Biopharma’s NXC-201 Therapy — Sees Over 190% Upside In IMMX Stock
Immix Biopharma’s latest clinical results showed strong patient responses to its lead CAR-T candidate as the biotech firm prepares for a planned regulatory filing in 2027.
Immix Biopharma, Inc. (IMMX) Shareholder/Analyst Call Transcript
Immix Biopharma, Inc. (IMMX) Shareholder/Analyst Call September 29, 2026 8:00 AM EDTCompany ParticipantsIlya Rachman - Co-Founder, CEO, Chief Scientific...
Immix Biopharma Reports 89% Complete Response Rate in Phase 2 NXC-201 Trial
Immix Biopharma, Inc. (NASDAQ:IMMX) reported interim data from its NEXICART-2 Phase 2 clinical trial of NXC-201 in patients with relapsed or refractory AL amyloidosis.
Needham Maintains Buy on Immix Biopharma, Raises Price Target to $30
Needham analyst Gil Blum maintains Immix Biopharma (NASDAQ:IMMX) with a Buy and raises the price target from $21 to $30.
Immix Biopharma Announces Pricing of $125 Million Underwritten Offering of Common Stock
LOS ANGELES, Sept. 29, 2026 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “we” or “us” or “IMMX”), a global leader in relapsed/refractory AL Amyloidosis, today announced the pricing of an underwritten registered offering of 11,363,637 shares of its common stock at a public offering price of $11.00 per share. The gross proceeds from this offering are expected to be $125 million, before deducting underwriting discounts and commissions and offering expenses payable by the Compan
Immix Biopharma Announces 89% Complete Response Rate at Interim Update Across All NEXICART-2 Patients, with MRD-Negativity Indicating Potential to Reach up to 98% Complete Response Rate, Supporting Potential Best-in-Class Therapy for Relapsed/Refractory AL Amyloidosis
– 100% (25/25) of new patients are either in complete response (CR) or MRD-negative (21/25 are in CR; remaining 4/25 are MRD-negative) – – To-date, all patients achieving MRD-negativity reached CR within one year of treatment – – Across all forty-five patients, NXC-201 produced an 89% (40/45) CR rate as assessed by independent review committee – – In four pending patients that are already MRD-negative, MRD-negativity in bone marrow predicts future CR, potentially increasing future CR rate up to
Mizuho Maintains Outperform on Immix Biopharma, Raises Price Target to $26
Mizuho analyst Graig Suvannavejh maintains Immix Biopharma (NASDAQ:IMMX) with a Outperform and raises the price target from $15 to $26.
Related Stocks (Peers)
Recent Insider Transactions
| Date | Name | Shares Changed | Price | Value |
|---|---|---|---|---|
| 2026-05-22 | Ng Carey | +12,500 | - | - |
| 2026-05-22 | Ng Carey | +6,250 | - | - |
| 2026-05-22 | Morris Gabriel S | +500,000 | - | - |
| 2026-05-22 | Rachman Ilya M | +500,000 | - | - |
| 2026-05-22 | Chudnovsky Yekaterina | +12,500 | - | - |
| 2026-05-22 | Chudnovsky Yekaterina | +6,250 | - | - |
| 2026-05-22 | Hsu Jason | +12,500 | - | - |
| 2026-05-22 | Hsu Jason | +6,250 | - | - |
| 2026-05-22 | Marquet Magda | +12,500 | - | - |
| 2026-05-22 | Marquet Magda | +6,250 | - | - |
| 2026-05-22 | Adams Helen C. | +12,500 | - | - |
| 2026-05-22 | Adams Helen C. | +6,250 | - | - |
| 2026-05-22 | BUCHAN JANE | +12,500 | - | - |
| 2026-05-22 | BUCHAN JANE | +6,250 | - | - |
| 2026-05-22 | CHANG NANCY T | +12,500 | - | - |
| 2026-05-22 | CHANG NANCY T | +6,250 | - | - |
| 2025-12-10 | Rachman Ilya M | +746 | $6.67 | $4,976 |
| 2025-12-10 | Morris Gabriel S | +770 | $6.58 | $5,067 |
| 2025-12-08 | Morris Gabriel S | -60,000 | - | - |
| 2025-12-08 | Morris Gabriel S | -96,000 | - | - |
| 2025-12-08 | Morris Gabriel S | +156,000 | $0.8 | $124,800 |
| 2025-11-21 | CHANG NANCY T | +39,643 | - | - |